MLAB Stock Recent News
MLAB LATEST HEADLINES
LAKEWOOD, Colo., May 22, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 31, 2024. Mesa's Form 10-K will be filed the same day. The earnings announcement has been delayed as we finalize the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions.
LAKEWOOD, Colo., April 01, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 24, 2024.
LAKEWOOD, Colo., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2024 at approximately 8:00 A.M. Eastern time on Monday, February 5, 2024.
Mesa Labs ( MLAB ) is a small-cap medical provider of quality control monitoring and validation instruments serving niche markets in healthcare, industrial, pharmaceutical, medical and food processing applications. I have followed this small company for several years and traded the stock for profits in my Healthcare Innovators portfolio.
LAKEWOOD, Colo., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2024 at approximately 8:00 A.M. Eastern time on Monday, November 6, 2023.
LAKEWOOD, Colo., June 21, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2024 at approximately 8:00 A.M. Eastern time on Thursday, August 3, 2023.
Mesa Labs (MLAB) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $2.22 per share a year ago.
In Q3, Mesa Laboratories reported mixed results throughout the P&L with soft bottom-line fundamentals. FCF growth still lumpy with contraction in divisional growth.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Mesa Labs (MLAB) is well positioned to outperform the market, as it exhibits above-average growth in financials.